Search results
Showing 1 to 13 of 13 results for benralizumab
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.
Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.
Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.
This asthma pathway signposts recommendations and resources from the British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and Scottish Intercollegiate Guidelines Network (SIGN) on diagnosing, monitoring and managing asthma in adults, young people and children, so you can see what guidance is available all in one place.
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]
Awaiting development Reference number: GID-TA11360 Expected publication date: TBC
Benralizumab for previously treated severe nasal polyps [ID1659]
In development Reference number: GID-TA10818 Expected publication date: TBC
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]
Discontinued Reference number: GID-TA10995
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA777)
Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
In development Reference number: GID-TA11808 Expected publication date: TBC
Evidence-based recommendations on 12 standard quality house dust mite sublingual lyophilisate (SQ-HDM SLIT; Acarizax) for treating allergic rhinitis and allergic asthma caused by house dust mites.
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence